HALISTER: Bristol-Myers Cuts 2017 Adj. EPS Forecast; 4Q Opdivo Rev. Beats

Bristol-Myers Cuts 2017 Adj. EPS Forecast; 4Q Opdivo Rev. Beats

(Bloomberg) -- Bristol-Myers Squibb cuts 2017 adj. EPS view to $2.70-$2.90, saw $2.85-$3.05 on Oct. 27, est. $2.86.
  • Sees 2017 global rev. increasing in low-single digits
  • Sees 2017 gross margin 72%-73%, est. 73.9%
  • 4Q adj. EPS 63c, est. 67c (range 61c-71c)
  • 4Q rev. $5.24b, est. $5.12b (range $4.97b-$5.31b)
    • Opdivo $1.31b, est. $1.17b
    • Eliquis $948m, est. $967.2m
    • Orencia $625m, est. $607.5m
    • Sprycel $494m, est. $473.6m
    • Yervoy $264m, est. $299.9m
    • Hepatitis C franchise $226m, est. $256.8m
    • Empliciti $47m, est. $51.8m
  • BMY says forecast assumes no generic Sprycel competition in Europe following appeal of patent office decision
  • Conf. call 10:30am 877-201-0168, pw 60705823 or listen to it on LIVE
  • NOTE: Analysts focused on Opdivo after setback in lung cancer; see preview
Statement link
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
BMY US (Bristol-Myers Squibb Co)
4528 JP (Ono Pharmaceutical Co Ltd)
4578 JP (Otsuka Holdings Co Ltd)

To de-activate this alert, click here

UUID: 7947283

HALISTER1: *BLACKSTONE 4Q ECONOMIC EPS 68C, EST. 66C

*BLACKSTONE 4Q ECONOMIC EPS 68C, EST. 66C

Alert: HALISTER1
Source: BN (Bloomberg News)

Tickers
BX US (Blackstone Group LP/The)

People
Christine Anderson (Blackstone Group LP/The)
Joan Solotar (Blackstone Group LP/The)
Stephen Schwarzman (Blackstone Group LP/The)
Weston Tucker (Blackstone Group LP/The)

To de-activate this alert, click here
To modify this alert, click here

UUID: 7947283

HALISTER: Biogen FY Rev. View Trails Est.

Biogen FY Rev. View Trails Est.

(Bloomberg) -- Biogen sees FY rev. $11.1b to $11.4b, est. $12.1b
  • 4Q rev. $2.87b, est. $2.94b (range $2.75b-$3.07b)
  • 4Q adj. EPS $5.04, est. $4.96 (range $4.43-$5.50)
  • 4Q Tecfidera rev. $1.00b, est. $1.02b (Bloomberg data)
    • 4Q Tysabri rev. $473.9m, est. $506.9m
    • 4Q Alprolix rev. $93.2m, est. $90.5m (average of 12)
    • 4Q Eloctate rev. $149.0m, est. $138.6m (average of 12)
  • Sees 2017 adj. EPS $20.45 - $21.25
  • Sees 2017 adj. EPS $20.45 & $21.25
  • Ignore: Biogen CEO, Forward Pharma Pact Previously Reported
  • Sees 2017 rev. $11.1b to $11.4b, est. $12.1b
  • Sees 2017 rev. $11.1b to $11.4b
  • Sees 2017 adj. EPS $20.45 - $21.25, est. $21.03
NOTE:
  • 19 buys, 9 holds, 0 sells before today
  • Call 8am (NY time), (877)-650-1145 pw 45044921
Statement
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
BIIB US (Biogen Inc)

To de-activate this alert, click here

UUID: 7947283

HALISTER1: Former Billionaire Batista Sought by Brazil Police in Graft Case

Former Billionaire Batista Sought by Brazil Police in Graft Case

Alert: HALISTER1
Source: BN (Bloomberg News)

People
Eike Batista (EBX Group Co Ltd)
Michel Temer (Federative Republic of Brazil)
Sergio Cabral (State of Rio De Janeiro)
Sergio Moro (Federative Republic of Brazil)

To de-activate this alert, click here
To modify this alert, click here

UUID: 7947283